Introduction
Since the advent of combination antiretroviral therapy (cART), patients with HIV have longer life expectancies; however, chronic conditions, such as metabolic and cardiovascular disease (CVD), are becoming more prevalent in this population [1] . In addition to lifestyle factors, cART and HIV itself may be associated with metabolic syndrome in youth and adults that places them at risk for CVD [2] . Increased rates of insulin resistance have been reported in some studies of HIV-infected youth as has the presence of other risks factors for clinical CVD [3] [4] [5] [6] [7] [8] [9] .
In our initial study, we measured insulin resistance by the homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR) [10] among 402 perinatally HIV-infected (PHIVþ) youth (mean age 12.3 years, of whom 47% were male and $25% were prepubertal) enrolled in the Adolescent Master Protocol (AMP) of the Pediatric HIV/AIDS Cohort Study (PHACS). We found that 61 (15.2%) had insulin resistance and that insulin resistance was significantly associated with elevated alanine aminotransferase (ALT), Tanner stage 5 puberty, higher BMI, higher nadir CD4%, and ever having received amprenavir [11] . In that study, 45 youth had an oral glucose tolerance test (OGTT) of whom three (6.7%) had impaired fasting glucose (IFG) only, three (6.7%) had impaired glucose tolerance (IGT) only, and one other (2.2%) had both IFG and IGT. In addition, three of 43 tested (7.0%) had an HbA1c higher than 42 mmol/mol, but none was higher than 48 mmol/mol, one of the criteria for diagnosing diabetes as set forth by the American Diabetes Association (ADA) [12] . In the current follow-up study, we proposed to compare the prevalence of insulin resistance between PHIVþ adolescents and perinatally HIVexposed, but uninfected (PHEU) individuals, determine incidence rates of and contributory factors to both new and resolved cases of insulin resistance in PHIVþ adolescents, and evaluate abnormal glucose metabolism (by OGTTand HbA1c) in incident insulin resistance cases. We hypothesized that PHIVþ adolescents would have an increased prevalence of insulin resistance compared with PHEUs; incident cases of insulin resistance over time among HIVþ adolescents would be associated with increasing age, worsening body composition (e.g. increased adiposity accessed via BMI and waist circumference), less exercise, and specific ART use; and resolution of insulin resistance over time among HIVþ adolescents would be associated with young age, improving body composition (e.g. decreased truncal adiposity), more exercise, and antiretrovirals with better metabolic profiles.
Methods

Study population
The source population for this study was 451 PHIVþand 227 PHEU youth enrolled in the PHACS AMP, an ongoing prospective cohort study designed to evaluate the impact of HIV infection and cART on multiple domains in preadolescents and adolescents with perinatally acquired HIV infection. Between March 2007 and December 2009, youth from 15 study sites in the United States and Puerto Rico were eligible for enrollment into AMP if they were born to HIV-infected mothers, were between 7 and 16 years of age, and had available medical record history since birth on antiretroviral exposure, opportunistic infection prophylaxis, HIV viral load and CD4 þ cell count, and major medical events. The AMP protocol was approved by the institutional review board at each participating site and by that of the Harvard T.H. Chan School of Public Health. Written informed consent was obtained from each youth's parent or legal guardian, and assent was obtained from youth participants according to local institutional review board guidelines.
To be eligible for the current study, youth had to have had at least one simultaneously obtained set of centrally assessed fasting measurements of both plasma glucose and serum insulin and Tanner stage information. Exclusions included an ALT greater than three times the upper limit of normal or a diagnosis of hepatitis C, a diagnosis of diabetes or use of medication affecting blood glucose, and diagnoses of chronic renal disease, Cushing disease, or mitochondrial disease.
Outcome definition
Glucose and insulin levels (obtained after a fast of !8 hours) were measured centrally at the Diabetes Research Institute Clinical Chemistry Laboratory at the University of Miami Miller School of Medicine in the laboratory of Armando Mendez, PhD. From these glucose and insulin measurements, HOMA-IR was calculated according to the formula: [glucose (mmol/l) Â insulin (mU/ml)]/22.5.
Insulin resistance was defined for prepubertal individuals (less than Tanner stage 2) as HOMA-IR more than 2.5 and for pubertal individuals as more than 4.0 [13] . Pubertal assessments by Tanner staging for genitalia and pubic hair were done by physical examination by trained examiners and the maximum Tanner stage based on genitalia or pubic hair was assigned to the participant. Of the total HOMA-IR measurements among the study participants, 14% were missing a Tanner stage assessment on the visit that specimens were obtained for glucose and insulin. However, the majority of these missing Tanner stages (88%) had a previous Tanner stage 5 measurement and the remainder was imputed based on available longitudinal assessments of Tanner stage and expert opinion of the study pediatric endocrinologist (M.E.G.).
Prevalence of insulin resistance was assessed from the first centrally measured HOMA-IR measurement (i.e., baseline). Among PHIVþ participants, incidence of insulin resistance was assessed by following those without defined insulin resistance at baseline and resolution of insulin resistance was assessed by following PHIVþ participants with insulin resistance at baseline (i.e. prevalent cases of insulin resistance). Those children with incident insulin resistance were further characterized based on results of a 2-h OGTT and simultaneous HbA1c measurement. Abnormal glucose tolerance was defined according to the ADA criteria: IFG ¼ fasting glucose more than 5.5 mmol/l, but less than 6.9 mmol/l; IGT ¼ 2-h glucose (postglucose load) between 7.7 and 11.0 mmol/l; and diabetes mellitus ¼ fasting plasma glucose at least 6.9 mmol/l, 2-h glucose (postglucose load) at least 11.0 mmol/l, or HbA1c at least 48 mmol/mol [12] .
Covariates
Baseline variables evaluated for their association with incident insulin resistance or resolution of insulin resistance included demographic (sex, race/ethnicity, and age), metabolic (BMI, waist circumference, fasting lipids, physical activity, and diet), and HIV-specific (CD4 þ cell count, HIV viral load, and antiretroviral history) characteristics. The specific ART assessed for their association with insulin resistance included those reported to be associated with hyperglycemia (http:// www.globalrph.com/glycemia.htm): abacavir, didanosine, stavudine, amprenavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, and saquinavir. Current use of an ARTwas defined as use at baseline. An indicator of use of other medications known to be associated with hyperglycemia (http://www.globalrph.-com/glycemia.htm) was also a covariate of interest. All characteristics were collected either through self-report (e.g. race/ethnicity), clinical evaluation (e.g. BMI and waist circumference), or medical chart abstraction (e.g. immunological, virological, and ART characteristics). BMI was expressed as a z score for age and sex [14] . Dietary intakes and physical activity were assessed by child and adolescent-specific food frequency questionnaires and physical activity screeners developed by Block Dietary Data Systems (Nutriquest, Berkeley, California, USA) (http://nutritionquest.com/assessment/).
Statistical methods
A log-binomial model was fit to calculate an unadjusted prevalence ratio for insulin resistance comparing PHIVþ and PHEU participants, and prevalence ratios adjusted for Tanner stage, age, sex, and race/ethnicity. Inverse probability weights were used to adjust for Tanner stage and age. Cox proportional hazards models were used to identify factors associated with incident insulin resistance and resolution of insulin resistance. Covariates significantly associated with incident insulin resistance or resolution of insulin resistance at P < 0.10 or with univariable hazard ratios showing at least a 50% increase or decrease in the hazard of insulin resistance or resolution of insulin resistance were included in respective multivariable models. Due to the collinearity between BMI z score and waist circumference, separate multivariable models were fit, including each one individually with the other covariates. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, North Carolina, USA).
Results
Three hundred and sixty-two PHIVþ and 185 PHEU participants had at least one set of simultaneous glucose and insulin levels measured. After excluding three PHIVþ participants with type 2 diabetes mellitus, two on metformin, four with hepatitis C, one with chronic renal disease, and seven with high ALT values prior to or at baseline, 345 PHIVþand 185 PHEU participants were available for analyses. PHIVþ were older than PHEU (mean age 15 versus 11.1 years) at baseline. A larger proportion of PHIVþ participants had also achieved sexual maturation (Tanner stage 5) at baseline compared with PHEU participants (52 versus 12%). The unadjusted prevalence of insulin resistance in the PHIVþ was 27.3% [95% confidence interval (CI) 22.6-32.3%] versus 34.1% (95% CI 27.3-41.4%) in the PHEU group. After adjustment for Tanner stage, age, sex, and race/ethnicity, however, there was no significant difference in the prevalence of insulin resistance between the two groups [prevalence ratio (95% CI) 1.02 (0.70-1.48)].
After excluding the 94 PHIVþ participants with insulin resistance at baseline, the incidence of insulin resistance over follow-up among the remaining 251 PHIVþ participants was 14.6/100 person-years (95% CI 11.2-18.8/100 person-years, N ¼ 62 cases, 423.2 person-years at risk). At the start of follow-up, mean (SD) age was 15.1 (2.9) years, 51% were females, mean (SD) BMI z score was 0.0 (1.1), and mean (SD) waist circumference was 73.5 AE 11.4 cm ( Table 1) . Factors positively associated with the development of insulin resistance assessed by (4) 1 (2) 10 (5) 2 27 (11) 10 (16) 17 (9) 3 43 (17) 14 (23) 29 (15) 4 41 (16) 7 (11) 34 (18) 5 129 (51) 30 (48) 99
11 (4) 
30 (12) 8 (13) 22 (12) 
16 (6) 5 (8) 11 (6) Triglycerides >1.2 mmol/l (age <10 years) or >1.7 mmol/l (age !10 years), N (%)
39 (16) 7 (11) 32 (17) HDL cholesterol < 0.9 mmol/l, N (%) 32 (13) 8 (13) 24 (13) Use of medications associated with hyperglycemia -N (%)
61 (24) 14 (23) 47 (25) Log 10 viral load (log 10 copies/ml)
151 ( (14) univariable analysis included female sex, higher BMI z score, and higher waist circumference. Race/ethnicity and fasting lipids were not associated with insulin resistance. Viral load, CD4 þ cell count, history of AIDS-defining event, and specific antiretroviral use were not significantly associated with incident cases of insulin resistance (Table 1) . Additionally, physical activity (min/ day), TV exposure, and carbohydrate/fat intake were not significantly associated with incident cases of insulin resistance (data not shown). In multivariable analyses, only higher BMI z score and waist circumference at baseline were significantly associated with development of insulin resistance, although females had a marginally significantly increased hazard of insulin resistance Closest measurement within 6 months prior to baseline. Among the 94 participants with insulin resistance at baseline, 43 had resolution of their insulin resistance over a follow-up of 155.4 person-years, yielding a resolution rate of 27.7/100 person-years (95% CI 20.0-37.3). At baseline, mean (SD) age was 14.8 (2.5) years, 59% were females, mean (SD) BMI z score was 1.1 (1.0), and mean (SD) waist circumference was 86.7 (16.2) cm (data not shown). Factors positively associated with resolution of insulin resistance assessed by univariable analysis included male sex and lower BMI z score. None of the other metabolic or HIV-specific factors, such as physical activity, diet, CD4 þ cell count, viral load, or specific ART use, were significantly associated with resolution of insulin resistance in univariable analyses. In multivariable analyses, only male sex and lower BMI z score were consistently associated with resolution of insulin resistance, although in the model including waist circumference, lower waist circumference was marginally associated with resolution of insulin resistance and those who used lopinavir/ritonavir at baseline were twice as likely to show resolution of insulin resistance (Tables 4 and 5 ). Of the 27 participants who used lopinavir/ritonavir at baseline, seven (26%) had switched from lopinavir/ritonavir at the time of resolution or the last visit.
Discussion
Insulin resistance is a contributor to the metabolic syndrome, a cluster of risk factors (in childhood including abdominal obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and elevated fasting plasma glucose) [15] that predisposes to CVD and type 2 diabetes. This was first described in HIV-infected adults 35 years ago [16] . The exact etiology of insulin resistance in the HIV setting remains unknown, but is likely multifactorial, with contributions from traditional risk factors (e.g. obesity, family history, and racial/ethnic 618 AIDS 2018, Vol 32 No 5 background), comorbid conditions (e.g. hepatitis C virus infection), Antiretroviral-related factors (e.g. direct effects of protease inhibitors, cumulative exposure to nucleoside reverse transcriptase inhibitors, hepatic steatosis, and fat redistribution), and HIV itself (e.g. chronic inflammation) [17] . Mechanistically, insulin resistance may result from an abnormal hormonal secretory profile by adipose tissue; noncompetitive, reversible direct inhibition of the insulin-responsive facilitative glucose transporter isoform 4 (GLUT4) in muscle and fat; and/or mitochondrial abnormalities including reduction in mitochondrial DNA (mtDNA) copies/cell and decreased oxygen consumption [18] [19] [20] [21] [22] .
We demonstrate in this study that the prevalence of insulin resistance in the PHIVþ children in PHACS/AMP was 27.3 and 34.1% in the PHEU group. After adjustments for Tanner stage, age, sex, and race/ethnicity, however, there was no significant difference in the prevalence of insulin resistance between the two groups. In this report, insulin resistance in the PHIVþ cohort was almost twice as prevalent as in our prior study [11] ; however, only five of 62 individuals who developed insulin resistance over time had an abnormality of glucose tolerance (versus 10 of 45 with insulin resistance in our previous study) and none met criteria for diabetes in either study. This contrasts with two cases of diabetes at baseline, with no incident cases, and no cases of IFG at baseline and two incident cases in the National Institute of Child Health and Human Development International Site Development Initiative (NISDI) Pediatric Latin American Countries Epidemiologic Study (PLACES) cohort [23] . This increase in prevalence of insulin resistance in the current study (compared to our prior report) is likely related to the older age and greater degree of pubertal maturation in the current PHIV cohort. Use of a central laboratory for assessment of insulin and glucose compared to local laboratories, as was done in the previous analysis, may also account for some of the difference in prevalence of insulin resistance among PHIV in both studies. [4, 7, 24, 25] , and 42.9% in Thailand [5] . A possible explanation for these disparate results includes the fact that different definitions of insulin resistance by HOMA are used in different series, reflecting a failure to adjust for the normally lower insulin sensitivity that occurs during puberty compared with prepuberty. Historically, the reported prevalence of insulin resistance is 25-33% in HIV-infected adults [26] . Of note, our current prevalence in HIVþ youth approximates the 34.9% prevalence of insulin resistance by HOMA-IR recently reported in 219 HIV-infected Peruvian adults with HIVon highly active ART [27] .
In a previous study of this cohort, PHEU children had higher BMI z scores than did PHIVþ, and were more likely to be obese [28] . Our finding of an approximately 30% prevalence of insulin resistance in both groups in the current analysis is substantially higher than the prevalence reported in over 2000 Korean nonoverweight, nonobese healthy adolescents (4.9%) [29] , but mirrors the high prevalence of insulin resistance found in otherwise healthy obese youth. In a study of 1356 obese youth (2-19 years), 53.8% of 9-11-year-olds, and 79.3% of those more than 12 years old manifested insulin resistance by HOMA-IR, although the cutoff used of 2.5 did not take into account the naturally decreased insulin sensitivity of puberty [30] . In a study of 100 obese Spanish youth (11.6 AE 2.7 years), the prevalence of insulin resistance was 29% by HOMA-IR [31] . Of note, other methods of assessment of insulin resistance may yield different prevalence of insulin resistance. For example, in the aforementioned Spanish study of non-HIV-infected obese youth, when defining insulin resistance by serum insulin responses to an oral glucose load, the prevalence of insulin resistance increased to 50% [30] , which may reflect greater sensitivity of detection of insulin resistance
Insulin sensitivity in HIVR adolescents Geffner et al. 619 Table 5 . Multivariable risk factors for resolution of insulin resistance among HIV-infected adolescents during follow-up (N U 87) (including waist circumference). derived from 2-h OGTT glucose and insulin data than by fasting values alone [32] . The gold standard for quantifying insulin resistance in adolescents is the euglycemic hyperinsulinemic clamp. The frequently sampled intravenous glucose tolerance test (FSIVGTT) and steady-state plasma glucose (SSPG) methods are also valid measurements. However, for large cohort studies, these methods are labor-intensive, require intravenous infusions and frequent blood sampling, are burdensome for participants, are expensive, and require a research setting for optimal performance [33] .
Longitudinal data regarding the natural history of insulin resistance in HIVþ children are relatively sparse [18] . In a Latin American cohort, 3.8% developed insulin resistance during follow-up (in addition to 5.5% of children who had insulin resistance at baseline) [23] . In multivariable analyses, only higher BMI z score and waist circumference were significantly associated with development of new insulin resistance in our study, although females had a marginally significantly increased risk of insulin resistance compared with males. Conversely, only male sex and lower BMI z score were associated with resolution of insulin resistance, although in the model including waist circumference, use of lopinavir/ritonavir at baseline was significantly associated with an over two-fold rate of resolution compared with no use at baseline. A lower waist circumference was also marginally associated with resolution of insulin resistance. The associations of female gender and increased BMI/waist circumference are not unexpected as these are well known to predict risk of insulin resistance in healthy populations [30] . Thus, it stands to reason then that resolution of insulin resistance would be greater in males and with decreasing BMI/waist circumference even in an HIVþ population.
Other studies have suggested a relationship between the use of protease inhibitors and insulin resistance. The association of improvement in insulin sensitivity that we found with usage of lopinavir/ritonavir is somewhat unexpected and of unclear etiology. Lack of adherence to lopinavir/ ritonavir is an unlikely explanation given that viral loads were higher during follow-up among those whose insulin resistance did not resolve. In normal men, short-term use of this combination leads to a deterioration in glucose tolerance at the 2-h time point of an OGTT, without a significant change in insulin-mediated glucose disposal rate as determined by a euglycemic hyperinsulinemic clamp [34] . In a cross-sectional study in consecutive HIV-infected adults treated with regimens containing efavirenz, lopinavir/ritonavir, or atazanavir, HOMA-IR was greatest in those individuals treated with lopinavir/ritonavir [35] . Furthermore, in adult men with HIV, the incidence of insulin resistance and metabolic syndrome was increased by use of lopinavir/ritonavir [36] .
Factors known to be associated with increasing insulin resistance in healthy children also include puberty and race/ethnicity [30] . Puberty was not a factor in our comparison between PHIV and PHEU youth as we adjusted for Tanner stage in statistical analysis. As to race/ ethnicity, there were no significant differences between groups recognizing that insulin resistance is ordinarily most common in African Americans and Hispanics, which constituted the bulk of our cohort ($90% in both groups) perhaps making it difficult to detect differences between other races/ethnicities.
There are strengths and limitations to the study. This is a well characterized longitudinal cohort in which glucose and insulin levels were assayed in a central laboratory to standardize measurements. We may have had limited power to detect differences in the incidence or resolution of insulin resistance by factors that are not common and we needed to impute Tanner staging in some participants who had not reached Tanner stage 5. Additionally, allocation to treatment with antiretrovirals was not randomized so that these drugs may have been used differently in groups that also had different insulin resistance risks.
Although only a small percentage of those youth in our study with insulin resistance, even when persistent, had associated disturbances in glucose metabolism, the possibility of future abnormalities, including type 2 diabetes, as well as development of other components of the metabolic syndrome, that is, high blood pressure and unfavorable lipid profiles, remains a concern as HIVinfected youth face an increasing risk of obesity in adulthood and a lifetime exposure to both HIV disease and its treatment.
